STAT+: Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases
Agios Pharmaceuticals said Monday that it is selling its cancer business to the French drug…
Category: STAT+
STAT+: A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust
WASHINGTON — David Kessler is not the obvious choice for any role in the Biden…
STAT+: Sacklers withdrew cash from Purdue over opioid lawsuit fears, documents show
In recent weeks, different members of the Sackler family that controls Purdue Pharma maintained they…
.jpg)
STAT+: World Health Organization says its Covid-19 vaccine program has secured 2 billion doses
After months of effort, a World Health Organization program has reached an agreement to obtain…
STAT+: Pharmalittle: FDA panel endorses Moderna Covid-19 vaccine; Sacklers dodge blame for opioid crisis at hearing
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list
The best and worst biopharma CEOs of 2020, selected by STAT+ readers, are Sam Kulkarni…
STAT+: Biogen to pay $22 million for illegally using charities to pay kickbacks to Medicare patients
Biogen (BIIG) has agreed to pay $22 million to resolve allegations that donations it paid…
STAT+: Former J&J exec sues for sexual discrimination and harassment, alleging ‘ruthless pattern of retaliation’
A 25-year veteran Johnson & Johnson (JNJ) executive has accused the health care giant of…
STAT+: Pharmalittle: Hospitals grapple with extra dose of Pfizer vaccine; FDA panel meets to review Moderna vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: AbbVie wins 21 months of wrinkle-free competition for Botox thanks to an ITC ruling
In a victory for AbbVie (ABBV), the U.S. International Trade Commission decided that imports of…
STAT+: Opioid prescribing has dropped dramatically since 2011, but experts say there’s ‘more to go’
Although the opioid crisis in the U.S. continues to make headlines, a new analysis finds…
STAT+: ‘It’s really on them to learn’: How the rapid rollout of AI tools has fueled frustration among clinicians
Hospice nurse Deborah Carlson had been hesitant to embrace the artificial intelligence tool her health…
.jpg)
STAT+: This tiny, one-drug biotech company is the loudest critic of Trump’s new international drug pricing policy
WASHINGTON — A tiny biosimilar company called Coherus Biosciences is emerging as one of the…
STAT+: In a stem cell experiment that seemingly failed, scientists see a possible way to prevent a devastating disease
The tiny mouse embryos were off to a promising start, many of them progressing from…
STAT+: Pharmalittle: One-quarter of the world won’t have a Covid-19 shot until 2022; naming a Covid vaccine takes time
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: Sage Therapeutics names former Alnylam exec Barry Greene as its new CEO
Sage Therapeutics is making a significant leadership change, hiring Barry Greene, the recently departed president…
STAT+: Here are the nominees for worst biopharma CEO of 2020
I told my editor that writing the worst CEOs of biopharma column is one of…
STAT+: Here are the nominees for best biopharma CEO of 2020
A year like no other requires a new way of drafting a list of Best…
STAT+: PhRMA took in a record $527 million in 2019, new records show
PhRMA, the pharmaceutical industry trade group, took in nearly $527 million in revenue last year,…
STAT+: State attorneys general urge HHS to penalize drug makers for cutting discounts to hospitals
More than two dozen state attorneys general are urging federal authorities to fine several large…
STAT+: Sackler family members agree to testify at House hearing on Purdue’s role in opioid crisis
In an unexpected development, two members of the Sackler family, which controls Purdue Pharma, will…
STAT+: A new biotech tries to bridge the drug innovation gap between East and West
A growing number of Chinese biotech companies are trying to bridge the drug innovation gap…
STAT+: Pharmalittle: FDA’s Hahn insists Pfizer vaccine was authorized as soon as possible; AstraZeneca to pay $39 billion for Alexion
Good morning, everyone and welcome to another working week. We hope the weekend respite was…
STAT+: AstraZeneca to acquire Alexion for $39 billion, adding blockbuster immune medicines
AstraZeneca on Saturday said it was acquiring Alexion Pharmaceuticals for $39 billion, marking a significant…
STAT+: Hospital groups sue HHS for failing to stop drug makers from cutting medication discounts
A group of hospital associations filed a lawsuit accusing the Department of Health and Human…
STAT+: World Trade council fails to act on proposal to waive IP rights to Covid-19 drugs and vaccines
In a widely anticipated meeting, a World Trade Organization council failed to act on a…
STAT+: A historian was cited to support making Purdue a public benefit company. He actually thinks it’s a bad idea
For the past few weeks, a U.S. bankruptcy court has heard objections to a plan…
STAT+: Pharmalittle: FDA panel endorses Pfizer Covid-19 vaccine; meanwhile, Sanofi shot suffers major setback
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment
Mergers and acquisitions have long been a vehicle for growth in the pharmaceutical industry. They…
STAT+: In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition
Arguing the Food and Drug Administration is precluding competition for biosimilar manufacturers, Boehringer Ingelheim has…
STAT+: New biotech backed by Third Rock launches with $81 million to go after ALS, other diseases
A new biotechnology company was launched Thursday in Cambridge with $81 million in funding, joining…
STAT+: Supreme Court upholds controversial Arkansas law that regulates pharmacy benefit managers
In a blow to pharmacy benefit managers, the U.S. Supreme Court ruled that an Arkansas…
STAT+: Pharmalittle: FDA advisers reviewing Pfizer Covid-19 vaccine today; White House hits roadblock on drug discount cards
Hello, everyone, and how are you today? We are doing just fine, thank you. Clear,…
STAT+: Biden’s HHS pick, Becerra, has taken in more campaign cash from health groups than any other industry
WASHINGTON — Xavier Becerra, President-elect Biden’s pick to lead the Department of Health and Human…
STAT+: Florida finds pharmacy benefit managers are benefiting from a lucrative profit center
As states struggle to control the cost of prescription medicines, a new report found pharmacy…
STAT+: Pharmalittle: AstraZeneca missteps undermined faith in its Covid-19 vaccine; U.S. jockeys with other countries for Pfizer shot
Rise and shine, everyone, another busy day is on the way. In fact, the middle…
STAT+: Marking a new rivalry with Apple, Google launches its own health studies app
Google made a major move into health research on Wednesday, unveiling a new smartphone app…
‘I just white-knuckle it’: Hemophilia patients pin their hopes on the revival of Vioxx to fill a void in pain relief
After surviving hemophilia, hepatitis C, and HIV, Joseph Burke considers himself a walking miracle. But…
STAT+: ‘Why would we ever go back?’: Covid-driven shift to remote cancer clinical trials will likely outlast the pandemic
The coronavirus pandemic has presented an extreme challenge for cancer clinical trials, with many shutting…
STAT+: Federal watchdog urged to investigate the FDA’s handling of Biogen Alzheimer’s drug
A federal watchdog is being asked to investigate the Food and Drug Administration for an…
STAT+: Pharmalittle: FDA staff backs Pfizer Covid-19 vaccine; Trump administration failed to lock in larger vaccine supply
Hello, everyone, and how are you today? We are doing just fine, thank you, now…
STAT+: Families tell U.N. Vertex is violating human rights with cystic fibrosis drug pricing
In an unusual move, a coalition of cystic fibrosis patients and their families have filed…
STAT+: 3 reasons the drug industry should be worried about Biden’s HHS pick, Xavier Becerra
WASHINGTON — For a pharmaceutical industry that has spent two years sparring with health secretary…
STAT+: Months of limbo at OpenBiome put fecal matter transplants on hold across the country
New regulations put in place because of Covid-19 have left one of the largest U.S….
STAT+: FDA finds fault with a Bristol plant, but it may not upset key approval of a cancer drug
The Food and Drug Administration found problems during a recent inspection of a Bristol Myers…
STAT+: Divergent results from Agios, Forma trials for their sickle cell disease drugs
Two drug makers — Forma Therapeutics and Agios Pharmaceuticals — are each developing their own…
STAT+: With new data and a storied history, Eli Lilly’s blood cancer pill is looking stronger
Three years ago, the biotech firm Loxo Oncology purchased a promising blood cancer pill for…
STAT+: Pharmalittle: Biden taps HHS and CDC heads; U.S. taxpayers may get a payback on Gilead’s remdesivir
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A payoff for U.S. taxpayers? CDC may have claims on remdesivir patents held by Gilead
Six years ago, a team of scientists at the Centers for Disease Control and Prevention…
STAT+: Constellation’s blood cancer drug shows greater benefit, easing concerns about its future
More patients and an improved response rate might once again shift the sentiment on Constellation…